Trials / Completed
CompletedNCT03945539
A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult Participants
An Open-label, Fixed-sequence, Drug-drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of JNJ-56136379 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Janssen Sciences Ireland UC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to assess the effect of itraconazole at steady-state on a single-dose pharmacokinetic (PK) of JNJ-56136379 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-56136379 | Participants will receive JNJ-56136379 orally on Day 1 in Treatment Period 1 and on Day 38 in Treatment Period 2. |
| DRUG | Itraconazole | Participants will receive 200 mg of itraconazole once daily orally for 21 days starting on Day 34. |
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2019-10-04
- Completion
- 2019-10-04
- First posted
- 2019-05-10
- Last updated
- 2025-02-03
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03945539. Inclusion in this directory is not an endorsement.